Safety, Tolerability, and Pharmacokinetics of Single Rising s.c. (Stage 1) and i.v. (Stage 2) Doses of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers (Double-blind, Randomized, Placebo-controlled Within Dose Groups)

Trial Profile

Safety, Tolerability, and Pharmacokinetics of Single Rising s.c. (Stage 1) and i.v. (Stage 2) Doses of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers (Double-blind, Randomized, Placebo-controlled Within Dose Groups)

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Risankizumab (Primary) ; Risankizumab (Primary)
  • Indications Ankylosing spondylitis; Asthma; Crohn's disease; Psoriasis
  • Focus Adverse reactions
  • Sponsors AbbVie; Boehringer Ingelheim
  • Most Recent Events

    • 05 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 16 Nov 2016 Planned End Date changed from 1 Apr 2017 to 1 Jun 2017.
    • 16 Nov 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top